Latest Medical Imaging News

Artrya has signed a five-year agreement with Huntsville Hospital Health System, converting the first participant in its SAPPHIRE Study into a commercial customer. The deal carries a minimum contracted value of US$0.5 million for Salix Coronary Anatomy, with further usage-based revenue possible from other modules.

Imagion Biosystems has secured central ethics approval for its US Phase 1b/2 trial of the MagSense HER2 imaging agent, removing a key requirement before recruitment can begin. Site activation is now underway, but no patient has yet been enrolled and the announcement provides no clinical data.

Telix has secured FDA Fast Track designation for BiPASS, its Phase 3 program testing 68Ga-PSMA-PET alongside MRI before prostate biopsy. The milestone may support closer FDA engagement and faster review of a planned NDA, but the indication remains investigational and no BiPASS results were disclosed.

TrivarX has made Stabl-Im its central development bet, but the ASX-listed health technology company also reported an $8.76 million FY2026 loss and an auditor-flagged material uncertainty over its ability to continue without further funding. The planned Phase 1 study remains subject to regulatory, ethics and operational clearances.

Singular Health has signed a non-binding MOU to build and operate a medical imaging repository for Florida Medicaid, with approximately A$3.5 million of potential revenue subject to definitive agreements and delivery. The project could give its 3DICOM platform a state-funded infrastructure reference site, but recurring funding remains unassured.

Micro-X has secured an eight-month, US$0.75 million contract extension from the US Department of Homeland Security to upgrade its miniature CT baggage scanner for scaled manufacturing. The award advances a technology platform towards possible commercial use, but does not yet represent a product sale or customer deployment.

Enlitic has secured a US$806,000 contract to migrate 10.6 million medical imaging studies for University of Michigan Health-Sparrow. The project also gives its Ensight platform a first active integration with Sectra’s enterprise imaging environment.

TrivarX has moved Stabl-Im closer to human testing, with pre-clinical studies underway, investigational product preparation progressing and clinical site selection now open. The indicative plan targets first participant enrolment in Q1 2027, but key technical and ethics steps remain outstanding.

CurveBeam AI has raised A$1.75 million through an oversubscribed SPP shortfall offer and placement, lifting its recent capital raised to A$7.36 million. The funds will support the HiRise China launch, product development, supply-chain preparation and working capital.

Resonance Health has signed a 24-month alliance with London-based Image Analysis Group, making its quantitative MRI endpoints orderable across IAG’s global clinical-trial network. The opportunity is potentially significant, but remains uncontracted: two pilot studies come first, with no minimum revenue or volume commitments.

CurveBeam AI has secured FDA 510(k) clearance for CT-based bone mineral density measurement, establishing the first regulatory step towards a potential new SaaS offering. The more commercially significant HiRise weight-bearing application still requires a separate clearance.

Imagion Biosystems has signed nanoComposix to resume GMP-aligned manufacturing of the MagSense nanoparticle core, a move designed to support its FDA-cleared HER2 breast cancer programme without the fixed cost of an in-house facility. The agreement improves manufacturing readiness, but its value, duration and production commitments remain undisclosed.